Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Novartis, ProMetic Biosciences Sign Vaccine Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

Novartis, ProMetic Biosciences Sign Vaccine Pact

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

ProMetic Life Sciences, Inc.’s UK subsidiary, ProMetic Biosciences, Ltd. (PBL), has entered into an agreement with Novartis Vaccines and Diagnostics to develop a synthetic-ligand affinity adsorbent for the purification of a recombinant protein vaccine. Under the terms of the agreement PBL will receive funding from Novartis to screen its Chemical Combinatorial Libraries for ligands suitable for the process scale purification of a new vaccine product by Novartis currently undergoing clinical trials. The work will be conducted at PBL’s research laboratories at the Cambridge Science Park, UK. Financial details were not disclosed.

According to Dr. Steve Burton, chief executive officer of PBL, “We are proud to have been selected by Novartis for this exciting project. This latest agreement is further recognition of PBL’s prominence and successful track record in the development of affinity ligand products for bioprocess applications.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics